OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares OPKO

OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a

OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.

OPKO Health (NASDAQ: OPK - Get Free Report) and Hypertension Diagnostics (OTCMKTS:HDII - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares OPKO Health

OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.

MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th.

OPKO Health (NASDAQ: OPK - Get Free Report) and Sintx Technologies (NASDAQ: SINT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Analyst Recommendations This is a summary of

OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago.